Jan H M Schellens Selected Research

Capecitabine (Xeloda)

11/2023	A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.
5/2020	Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
12/2019	Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
1/2019	Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.
11/2018	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
1/2018	Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
2/2016	Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
1/2016	Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
1/2016	A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
12/2015	Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan H M Schellens Research Topics

Disease

186	Neoplasms (Cancer) 05/2024 - 04/2002
70	Breast Neoplasms (Breast Cancer) 01/2020 - 04/2002
20	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 11/2002
19	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 09/2004
15	Neutropenia 01/2020 - 05/2002
12	Nausea 01/2021 - 09/2007
11	Melanoma (Melanoma, Malignant) 05/2024 - 09/2002
11	Carcinoma (Carcinomatosis) 01/2023 - 10/2003
10	Fatigue 01/2021 - 09/2011
9	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 02/2007
8	Disease Progression 01/2022 - 11/2007
8	Vomiting 01/2021 - 09/2007
8	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 01/2002
8	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 05/2007
7	Dihydropyrimidine Dehydrogenase Deficiency 01/2024 - 01/2012
7	Diarrhea 01/2020 - 09/2011
6	Exanthema (Rash) 01/2021 - 06/2011
6	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2006
6	Thrombocytopenia (Thrombopenia) 01/2020 - 06/2005
5	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 03/2005
5	Hypertension (High Blood Pressure) 01/2017 - 12/2009
4	Adenocarcinoma 01/2023 - 03/2010
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 09/2004
4	Stomach Neoplasms (Stomach Cancer) 02/2016 - 03/2010
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2013 - 08/2002
3	Glioma (Gliomas) 01/2023 - 04/2005
3	Ototoxicity 01/2021 - 02/2006
3	Fever (Fevers) 01/2021 - 07/2009
3	Hyperphosphatemia 01/2020 - 01/2017
3	Circulating Neoplastic Cells 01/2020 - 12/2011

Drug/Important Bio-Agent (IBA)

40	Proteins (Proteins, Gene)FDA Link 09/2017 - 04/2002
23	Biomarkers (Surrogate Marker)IBA 01/2018 - 03/2005
20	Capecitabine (Xeloda)FDA Link 11/2023 - 03/2004
18	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 08/2002
18	Gemcitabine FDA Link 01/2020 - 11/2002
18	Docetaxel (Taxotere)FDA Link 01/2020 - 11/2004
17	Tyrosine Kinase InhibitorsIBA 12/2018 - 04/2005
16	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 08/2016 - 10/2004
15	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 11/2006
13	PlatinumIBA 01/2021 - 05/2002
11	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024 - 12/2011
11	Monoclonal AntibodiesIBA 01/2023 - 08/2009
11	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 04/2004
10	olaparibIBA 01/2021 - 07/2009
10	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 05/2004
10	Adenosine Triphosphate (ATP)IBA 07/2017 - 10/2002
9	Fluorouracil (Carac)FDA LinkGeneric 05/2020 - 01/2006
9	Trastuzumab (Herceptin)FDA Link 01/2018 - 08/2009
8	pazopanib FDA Link 06/2018 - 11/2011
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2008
8	Topotecan (Hycamtin)FDA LinkGeneric 07/2009 - 01/2002
7	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 09/2002
7	Cetuximab (Erbitux)FDA Link 10/2019 - 05/2011
7	Peptides (Polypeptides)IBA 12/2011 - 01/2010
7	N- (3- chloro- 7- indolyl)- 1,4- benzenedisulphonamide (E7070)IBA 10/2011 - 09/2002
6	trametinibIBA 01/2023 - 01/2018
6	dabrafenibIBA 01/2023 - 03/2015
6	Phosphotransferases (Kinase)IBA 12/2018 - 08/2010
6	ErbB Receptors (EGF Receptor)IBA 01/2018 - 08/2008
6	Tamoxifen FDA LinkGeneric 01/2017 - 01/2013
6	Ritonavir (Norvir)FDA Link 03/2016 - 04/2004
6	Blood Proteins (Serum Proteins)IBA 07/2010 - 03/2006
6	TrabectedinIBA 01/2009 - 04/2002
5	CamptothecinIBA 01/2022 - 12/2004
5	Type I DNA Topoisomerases (Topoisomerase I)IBA 03/2020 - 01/2002
5	ElacridarIBA 01/2018 - 10/2004
5	AnthracyclinesIBA 01/2018 - 04/2002
5	Cytochrome P-450 CYP3AIBA 02/2016 - 01/2006
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2016 - 08/2007
5	EnzymesIBA 02/2015 - 01/2006
5	Irinotecan (Camptosar)FDA LinkGeneric 04/2013 - 09/2004
5	DNA AdductsIBA 07/2009 - 09/2002
4	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 01/2024 - 01/2006
4	TabletsIBA 01/2021 - 06/2013
4	Panitumumab (Vectibix)FDA Link 01/2020 - 12/2015
4	Estrogen ReceptorsIBA 01/2018 - 12/2013
4	human ERBB2 proteinIBA 01/2018 - 01/2016
4	Bevacizumab (Avastin)FDA Link 02/2016 - 05/2011
4	lenvatinibIBA 02/2015 - 08/2010
4	Imatinib Mesylate (Gleevec)FDA Link 06/2014 - 04/2005
4	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2014 - 10/2005
4	Methotrexate (Mexate)FDA LinkGeneric 02/2012 - 08/2004
3	UracilIBA 01/2022 - 07/2016
3	Messenger RNA (mRNA)IBA 10/2021 - 04/2002
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021 - 08/2012
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 05/2010
3	PolymersIBA 01/2021 - 05/2004
3	ProdrugsIBA 05/2020 - 11/2008
3	LigandsIBA 01/2020 - 01/2015
3	Lapatinib (GW572016)FDA Link 01/2020 - 08/2007
3	Epithelial Cell Adhesion MoleculeIBA 01/2020 - 01/2016
3	Capsules (Microcapsules)IBA 01/2020 - 01/2018

Therapy/Procedure

55	Therapeutics 12/2023 - 04/2002
22	Drug Therapy (Chemotherapy) 11/2023 - 04/2002
8	Radiotherapy 01/2021 - 08/2006
7	Drug Tapering 01/2019 - 05/2007
6	Oral Administration 01/2020 - 06/2004
4	Aftercare (After-Treatment) 03/2016 - 04/2004
3	Castration 01/2022 - 01/2019
3	Intravenous Administration 01/2020 - 05/2007